IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:		on of:	Dean Y. Li		
				Confirmation No.	
Application No.:			10/519342	2504	
Filed:			September 21, 2005		
For:			METHODS AND COMPOSITIONS FOR MANUPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS		
Group Art Unit:			1647		
Examiner:			David S. Romeo		
Attorney Docket No.:			: 38623/19.1		
Date:			September 24, 2009		
TO TH			MENTAL INFORMATION DISCLOSURE S ONER FOR PATENTS:	<u>TATEMENT</u>	
1.	Pursuant to the duty of disclosure, documents listed on the accompanyi PTO-1449 (or equivalent) are presented for the Examiner's consideration				
			of listed U.S. patents and U.S. patent applicated for submission. (37 C.F.R. § 1.98(a)(2)(ii))	ion publications are not	
	\boxtimes		of listed foreign patent documents and/or non- ed. (37 C.F.R. § 1.98(a)(2))	-patent literature are	
		PTO-1 U.S. Pa applica inform	of the documents listed at (sheet/cite no.) 449 (or equivalent) are omitted because (1) thatent Application No	ey are already of record in , on which this .S.C. § 120; and (2) any ion of Application	
		attache	of copending U.S. Patent Application No, for, listed at (sheet/cird Form PTO-1449 (or equivalent), ☐ is enclored if available via IFW. 1287 OG 16	te no.) of the sed / is omitted.	
2.	This information		on disclosure statement is being submitted (ch	eck box a., b., or c.):	
	a.		Within three months of the filing date of a nat of the national stage in an international applic mailing of a first Office action on the merits; of the the filing of a request.	ation; or before the or before the mailing of a	

			1.97(e) is required.); or			
	b.	After the period set forth in paragraph 2a, but before the mailing of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or				
		i.	The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or			
		ii.	A statement specified by 37 CFR 1.97(e) is set forth below; or			
	c.		After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is the \$18.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).			
3.	Fee Pa	e Payment				
	a.		A check in the amount of \$ is enclosed.			
	b.	\boxtimes	Payment by credit card.			
	c.		Please charge our Deposit Account No in the amount of \$			
	d.		The Commissioner is hereby authorized to charge any additional fees which may be required in connection with filing of these papers, or credit overpayment to Deposit Account No. 502375.			
4.	If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent si below hereby states that:					
		each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or				
		applica making inform 37 CF	of information contained in this information disclosure statement was a communication from a foreign patent office in a counterpart foreign tion, and, to the knowledge of the person signing the certification after reasonable inquiry, no item of information contained in this attion disclosure statement was known to any individual designated in 1.56(c) more than three months prior to the filing of the information ure statement.			

5.	A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.				
	Respectfully submitted,				
	By: /Samuel E. Webb/				
	Registration No. 44,394				

STOEL RIVES LLP 600 University Street, Suite 3600 Seattle, WA 98101 Telephone: (206) 624-0900 Facsimile: (206) 386-7500